Journal article icon

Journal article

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

Abstract:
Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels.

Methods A phase II randomized clinical trial of 123 patients with Her2-negative breast cancer was conducted, with patients treated with neoadjuvant chemother... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1186/s13073-018-0601-y

Authors


Höglander, EK More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM
Subgroup:
BDI-NDM
ORCID:
0000-0002-7572-3196
Lingjærde, OC More by this author
Silwal-Pandit, L More by this author
Expand authors...
Publisher:
BMC Publisher's website
Journal:
Genome medicine Journal website
Volume:
92
Issue:
10
Publication date:
2018-11-29
Acceptance date:
2018-11-13
DOI:
ISSN:
1756-994X
Pubs id:
pubs:953457
URN:
uri:f84a5f0f-d359-4834-8cbb-a1e886098020
UUID:
uuid:f84a5f0f-d359-4834-8cbb-a1e886098020
Local pid:
pubs:953457

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP